Afya is expected to report Q2 2026 revenue of $168.4 million and EPS of $0.49, with the current stock price of $17.42 trading well below the average analyst price target of $23.15.
Investors are primarily focused on the growth of medical school seats and the successful integration of recent acquisitions into the broader medical education ecosystem.
Recent performance has been driven by strong organic growth in the undergraduate segment, which remains the company's primary high-margin revenue engine. Analysts are looking for confirmation that Adjusted EBITDA margins can remain resilient despite persistent inflationary pressures in the Brazilian education sector.